Dorzolamide (Ophthalmic)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Open-angle glaucoma — elevated IOP | Adults and paediatric patients | Monotherapy or adjunctive | FDA Approved |
| Ocular hypertension — IOP reduction | Adults and paediatric patients | Monotherapy or adjunctive | FDA Approved |
Dorzolamide was the first topical carbonic anhydrase inhibitor (CAI) approved for ophthalmic use (FDA approval 1994). It was developed through structure-based drug design to deliver the IOP-lowering benefits of systemic CAIs (such as acetazolamide) via a topical route, thereby avoiding the significant systemic adverse effects associated with oral agents. In clinical studies, dorzolamide lowered IOP by approximately 3–5 mmHg throughout the day, and this effect was consistent for up to one year. Dorzolamide is primarily used as adjunctive therapy when prostaglandin analogues or beta-blockers alone do not achieve target IOP, and it is available in a fixed-dose combination with timolol (Cosopt) for improved adherence.
Cystoid macular oedema (CME): Topical dorzolamide has been used off-label for the management of macular oedema associated with conditions such as retinitis pigmentosa and post-surgical CME, based on its ability to inhibit carbonic anhydrase in the retinal pigment epithelium and enhance fluid absorption. (Evidence quality: Low)
Paediatric glaucoma: Although not carrying a formal paediatric age restriction, dorzolamide is used in paediatric patients including infants, supported by a 3-month controlled trial demonstrating a comparable adverse reaction profile to adults. (Evidence quality: Moderate)
Dorzolamide Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Open-angle glaucoma or ocular hypertension — monotherapy | 1 drop 2% in affected eye(s) TID | Same as starting dose | 1 drop TID | Expected IOP reduction: 3–5 mmHg Efficacy of less-than-TID dosing not established (FDA PI) |
| Adjunctive therapy — with prostaglandin analogue, beta-blocker, or alpha-agonist | 1 drop 2% in affected eye(s) TID | Same as starting dose | 1 drop TID | Separate all topical drops by at least 5 minutes Provides additive IOP lowering when combined with other classes |
| Fixed combination with timolol (Cosopt) — adults | 1 drop (dorzolamide 2%/timolol 0.5%) in affected eye(s) BID | Same as starting dose | 1 drop BID | Simplifies regimen from dorzolamide TID + timolol BID See Cosopt PI for complete prescribing details |
| Paediatric glaucoma | 1 drop 2% in affected eye(s) TID | Same as starting dose | 1 drop TID | Safety demonstrated in 3-month controlled paediatric trial Adverse reaction profile comparable to adults (FDA PI) |
Approximately 25% of patients experience a bitter or unusual taste following dorzolamide instillation, caused by the drug draining through the nasolacrimal duct into the oropharynx. Applying nasolacrimal occlusion (digital pressure at the inner canthus for 1–2 minutes) after each drop significantly reduces this side effect as well as systemic absorption. This is a common reason for patient dissatisfaction and should be proactively addressed during counselling.
Administration Guidance
Remove contact lenses before instillation and wait at least 15 minutes before reinserting — the solution contains benzalkonium chloride 0.0075%, which can be absorbed by and discolour soft contact lenses. When using multiple topical ophthalmic products, separate each by at least 5 minutes. Store at 15–30°C. Protect from light. After opening, use until the expiration date on the bottle.
Pharmacology
Mechanism of Action
Dorzolamide hydrochloride is a potent inhibitor of human carbonic anhydrase II (CA-II), with approximately 4,000-fold selectivity over CA-I. Carbonic anhydrase is an enzyme found in many body tissues including the ciliary processes of the eye, where it catalyses the reversible hydration of carbon dioxide to bicarbonate. In the ciliary epithelium, inhibition of CA-II reduces bicarbonate ion formation, which decreases sodium and fluid transport into the posterior chamber, ultimately reducing aqueous humour secretion and lowering IOP. Unlike systemic CAIs such as acetazolamide, topical dorzolamide achieves therapeutic concentrations in the ciliary processes (2–10 μM) while maintaining plasma free drug concentrations approximately 200-fold lower than those needed for systemic effects, providing a favourable local-to-systemic activity ratio.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Corneal absorption; peak aqueous humour concentration ~1000 ng/mL at ~2 h after topical 2%; plasma concentrations generally below assay limit (<15 nM) | Excellent local ocular bioavailability with minimal systemic exposure; avoids metabolic acidosis and electrolyte disturbances seen with oral CAIs |
| Distribution | Accumulates in RBCs by binding to CA-II (reaching 20–25 μM at steady state, ~8 days); plasma protein binding ~33%; plasma concentration ~0.034 μM (1/700 of RBC level) | RBC accumulation is the primary systemic reservoir; steady-state RBC concentrations reflect CA-II saturation rather than toxicity risk |
| Metabolism | Single N-desethyl metabolite formed; also binds to RBC carbonic anhydrase (primarily CA-I); less potent CA-II inhibitor than parent | Metabolite is pharmacologically less active; both parent and metabolite accumulate in RBCs and are slowly cleared |
| Elimination | Primarily renal excretion (unchanged drug + metabolite); RBC washout t½ ~4 months (~120 days); at steady state, renal excretion ~1.3 mg/day with renal clearance ~90 mL/min | Very long RBC elimination half-life; however, plasma free drug is too low to cause systemic CAI effects in healthy individuals; avoid in severe renal impairment (CrCl <30 mL/min) |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Ocular burning, stinging, or discomfort | ~33% (1 in 3 patients) | Occurs immediately following instillation; usually transient; most frequent adverse reaction |
| Bitter taste (dysgeusia) | ~25% (1 in 4 patients) | Due to nasolacrimal drainage to oropharynx; reduced by nasolacrimal occlusion; common reason for patient complaint |
| Superficial punctate keratitis | 10–15% | May be partly attributable to BAK preservative or low pH (5.6) of solution; monitor corneal surface |
| Ocular allergic reaction (signs and symptoms) | ~10% | May present as conjunctivitis, lid reactions, or contact allergy; may resolve on discontinuation |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Conjunctivitis / lid reactions | 1–5% | Chronic use may cause allergic-type reactions; resolve on discontinuation; evaluate before restarting (FDA PI) |
| Blurred vision | 1–5% | Transient; may occur with instillation |
| Eye redness | 1–5% | Mild conjunctival hyperemia |
| Tearing | 1–5% | Reflex lacrimation; self-resolving |
| Dryness / photophobia | 1–5% | May need sunglasses for photophobia; artificial tears for dryness |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Stevens-Johnson syndrome / toxic epidermal necrolysis | Very rare (sulfonamide class effect) | Days to weeks after initiation | Immediate discontinuation; emergency dermatology/medical care; fatalities reported (FDA PI). Sensitisation may recur on re-exposure regardless of route |
| Blood dyscrasias (agranulocytosis, aplastic anaemia) | Very rare (sulfonamide class effect) | Variable | Discontinue immediately; haematology referral; monitor blood counts |
| Fulminant hepatic necrosis | Very rare (sulfonamide class effect) | Variable | Discontinue; hepatology assessment; fatalities reported |
| Corneal oedema / decompensation | Uncommon; higher risk with low endothelial cell counts | Weeks to months | Monitor corneal thickness; discontinue if corneal oedema develops; avoid in patients with compromised corneal endothelium |
| Choroidal detachment (post-filtration surgery) | Rare (postmarketing) | Post-surgical | Ophthalmology assessment; may require discontinuation of aqueous suppressant therapy |
| Urolithiasis | Rare | Variable | Assess for renal calculi; CAI class effect from altered urinary pH and citrate excretion; consider discontinuation |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Ocular burning/stinging/discomfort | Leading ocular reason | Occurs in ~1/3 of patients; most tolerate with continued use but a subset discontinue |
| Bitter taste | Common patient complaint | Affects ~1/4 of patients; reducible with nasolacrimal occlusion technique |
| Allergic conjunctivitis / lid reactions | Reported with chronic use | FDA PI recommends discontinuation and evaluation before considering rechallenge |
Dorzolamide contains a sulfonamide moiety and is absorbed systemically despite topical administration. The FDA PI warns that the same types of severe reactions attributable to systemic sulfonamides may occur, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias. Fatalities have been reported, although rarely. Sensitisation may recur when a sulfonamide is re-administered regardless of route. Before prescribing, ask about sulfonamide allergy. If signs of serious reactions or hypersensitivity occur, discontinue immediately.
Drug Interactions
Dorzolamide has a limited systemic drug interaction profile due to very low plasma concentrations. The principal concerns relate to additive carbonic anhydrase inhibition when combined with oral CAIs and potential acid-base disturbances with high-dose salicylates.
Monitoring
- Intraocular PressureBaseline; 2–4 weeks; then every 3–6 months
RoutineExpected IOP reduction: 3–5 mmHg. Effect consistent throughout the day. Efficacy with less-than-TID dosing has not been established. - Corneal EndotheliumBaseline (specular microscopy if risk factors); periodically
Trigger-basedCA activity in corneal endothelium means CAI use carries risk of corneal oedema in patients with low endothelial cell counts. A 1-year study showed ~4% mean endothelial cell loss. Monitor corneal thickness if symptoms arise (hazy vision, haloes). - Ocular Surface / Allergy SignsEach visit
RoutineMonitor for conjunctivitis, lid reactions, and punctate keratitis. Allergic-type reactions reported with chronic use may resolve on discontinuation. Evaluate before considering rechallenge. - Sulfonamide Hypersensitivity SignsAt initiation and each visit
Trigger-basedAsk about skin rash, mucosal lesions, fever, or systemic symptoms. Discontinue immediately if SJS/TEN or other serious sulfonamide reaction suspected. - Renal FunctionBaseline; as clinically indicated
Trigger-basedDrug is not recommended in severe renal impairment (CrCl <30 mL/min) due to predominant renal excretion. Check renal function in elderly or those with comorbidities. - Visual FieldsPer glaucoma guidelines (every 6–12 months)
RoutineStandard automated perimetry for glaucomatous progression. Not specific to dorzolamide but essential for overall glaucoma management.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to dorzolamide, any component of the product, or other sulfonamides (FDA PI Section 4)
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment (CrCl <30 mL/min) — drug and metabolite excreted renally; not recommended by FDA PI (Section 8.6)
- Low corneal endothelial cell count — increased risk of corneal oedema due to CA inhibition in corneal endothelium; use with caution (FDA PI Section 5.3)
- Concurrent oral CAI therapy — additive systemic CA inhibition; concomitant use not recommended (FDA PI Section 7.1)
- Pregnancy — fetal vertebral malformations in rabbits at 37x clinical exposure; use only if benefit justifies risk (FDA PI Section 8.1)
Use with Caution
- History of sulfonamide allergy — although true cross-reactivity between ophthalmic CAIs and systemic sulfonamides is debated, the FDA PI includes the sulfonamide class warning
- Hepatic impairment — not studied; use with caution (FDA PI Section 8.6)
- Acute angle-closure glaucoma — additional therapeutic interventions are required beyond IOP-lowering agents (FDA PI Section 5.5)
- Contact lens wearers — BAK 0.0075% may discolour soft lenses; remove before instillation, reinsert after 15 minutes
- Breastfeeding — dorzolamide detected in milk of lactating rats; not known if excreted in human milk; weigh risk-benefit
Dorzolamide is a sulfonamide, and although administered topically, it is absorbed systemically. The FDA PI carries a warning that the same types of adverse reactions attributable to sulfonamides may occur with topical administration, including fatalities from Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias. Sensitisation may recur when a sulfonamide is re-administered irrespective of the route. If signs of serious reactions or hypersensitivity occur, dorzolamide must be discontinued immediately.
Patient Counselling
Purpose of Therapy
Dorzolamide eye drops are prescribed to lower the pressure inside the eye and protect against vision loss from glaucoma. The drops work by reducing the amount of fluid produced inside the eye. This medication controls the condition but does not cure it, so it must be used consistently three times daily, approximately 8 hours apart.
How to Take
Instil one drop into the affected eye(s) three times daily. After each drop, close the eye and press a fingertip against the inner corner of the eye near the nose for 1–2 minutes to reduce bitter taste and systemic absorption. If using other eye drops, wait at least 5 minutes between each. Remove contact lenses before use and wait 15 minutes before reinserting.
Sources
- Trusopt (dorzolamide hydrochloride ophthalmic solution) 2% — Full Prescribing Information (Merck). NDA 20408/S-052, revised December 2020. accessdata.fda.govPrimary source for all FDA-approved indications, dosing, contraindications, adverse reactions, PK data, and drug interactions used in this monograph.
- Dorzolamide hydrochloride ophthalmic solution 2% — Full Prescribing Information (generic, Sagent). Revised January 2026. drugs.comGeneric dorzolamide PI with identical clinical data; confirms adverse reaction rates and administration guidance.
- Strahlman E, Tipping R, Vogel R; International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide, timolol, and betaxolol. Arch Ophthalmol. 1995;113(8):1009–1016. PMID: 7639651.Major 1-year comparative trial establishing dorzolamide TID as an effective IOP-lowering agent with acceptable tolerability vs beta-blockers.
- Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111(10):1343–1350. PMID: 8216014.Early phase clinical trial establishing safety and dose-response characteristics of topical dorzolamide.
- Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110(4):495–499. PMID: 1562255.Dose-finding study establishing the 2% concentration as optimal for the balance of IOP efficacy and tolerability.
- European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th Edition. 2020. eugs.orgCurrent EGS guidelines positioning topical CAIs as adjunctive agents in glaucoma management.
- American Academy of Ophthalmology. Preferred Practice Pattern: Primary Open-Angle Glaucoma. 2020. aao.orgUS guideline discussing dorzolamide as second-line adjunctive therapy.
- Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19(1):87–112. PMID: 10614681.Comprehensive review of topical CAI pharmacology including dorzolamide’s selectivity for CA-II and mechanism of aqueous suppression.
- Maren TH, Conroy CW. A new class of carbonic anhydrase inhibitor. J Biol Chem. 1993;268(35):26233–26239. PMID: 8253744.Foundational biochemistry establishing dorzolamide’s high-affinity binding to CA-II and the structure-activity relationships underlying topical CAI design.
- Maren TH, Bar-Ilan A, Conroy CW, Brechue WF. Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that accumulates in the eye. Exp Eye Res. 1990;50(1):27–36. PMID: 2307710.Preclinical PK study of dorzolamide demonstrating corneal penetration, ciliary body concentrations, and the red blood cell accumulation kinetics.
- Biollaz J, Munafo A, Buclin T, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47(5):453–460. PMID: 7720769.RCT in healthy volunteers quantifying RBC washout half-life of ~120 days and confirming absence of clinically significant metabolic or renal effects with topical dosing.
- Maren TH, Brechue WF, Bar-Ilan A. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide. Exp Eye Res. 1992;55(1):73–79. PMID: 1397132.Comparative PK data providing context for dorzolamide’s local-to-systemic concentration ratio advantage over oral CAIs.
- Schmitz K, Banditt P, Motschmann M, Meyer FP, Behrens-Baumann W. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. Invest Ophthalmol Vis Sci. 1999;40(7):1621–1624. PMID: 10359348.Human aqueous humor PK study confirming peak dorzolamide concentrations of ~1000 ng/mL at approximately 2 hours after topical application.
- Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol. 1997;42(2):137–151. PMID: 9381368.Comprehensive clinical review of dorzolamide covering development history, PK, efficacy data, and its role in the glaucoma treatment ladder.